Johnson & Johnson's most recent trend suggests a bullish bias. One trading opportunity on Johnson & Johnson is a Bull Put Spread using a strike $121.00 short put and a strike $116.00 long put offers a potential 9.17% return on risk over the next 7 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $121.00 by expiration. The full premium credit of $0.42 would be kept by the premium seller. The risk of $4.58 would be incurred if the stock dropped below the $116.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Johnson & Johnson is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Johnson & Johnson is bullish.
The RSI indicator is at 73.13 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
Surprise: JNJ Just Did Celgene a Huge Favor
Thu, 07 Jul 2016 20:40:39 GMT
Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 data for DARZALEX® (daratumumab) and the Janssen Immuno-oncology Strategy and Portfolio
Thu, 07 Jul 2016 15:31:03 GMT
noodls – 09866947-0d16-456c-9b9f-91905aac9a54.pdf July 7, 2016 Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 data for DARZALEX® (daratumumab) and the Janssen Immuno-oncology Strategy …
Brexit or Bust: Should Healthcare Investors Worry About Brexit's Impact on Currencies?
Thu, 07 Jul 2016 12:22:00 GMT
Janssen and Johnson & Johnson to Provide Webcast Presentation on Phase 3 data for DARZALEX® (daratumumab) and the Janssen Immuno-oncology Strategy and Portfolio
Thu, 07 Jul 2016 11:30:00 GMT
PR Newswire – NEW BRUNSWICK, N.J., July 7, 2016 /PRNewswire/ — Janssen Research & Development, LLC and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast focused on Phase 3 data recently presented for …
U.S. judge cuts $500 mln verdict over J&J hip implants
Wed, 06 Jul 2016 17:19:27 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook